关注
Alberta Hoi
Alberta Hoi
Associate Professor, Monash University
在 monash.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Definition and initial validation of a lupus low disease activity state (LLDAS)
K Franklyn, CS Lau, SV Navarra, W Louthrenoo, A Lateef, L Hamijoyo, ...
Annals of the rheumatic diseases 75 (9), 1615-1621, 2016
6102016
Global epidemiology of systemic lupus erythematosus
MRW Barber, C Drenkard, T Falasinnu, A Hoi, A Mak, NY Kow, ...
Nature Reviews Rheumatology 17 (9), 515-532, 2021
3852021
Clinical associations of serum interleukin-17 in systemic lupus erythematosus
FB Vincent, M Northcott, A Hoi, F Mackay, EF Morand
Arthritis research & therapy 15, 1-9, 2013
1672013
Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice
AY Hoi, MJ Hickey, P Hall, J Yamana, KM O’Sullivan, LL Santos, ...
The Journal of Immunology 177 (8), 5687-5696, 2006
1542006
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ...
Arthritis research & therapy 19, 1-11, 2017
1382017
Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases
AY Hoi, MN Iskander, EF Morand
Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets …, 2007
1312007
TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy
SA Summers, A Hoi, OM Steinmetz, KM O’Sullivan, JD Ooi, D Odobasic, ...
Journal of autoimmunity 35 (4), 291-298, 2010
1302010
Brief report: interleukin‐38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus
I Rudloff, J Godsell, CA Nold‐Petry, J Harris, A Hoi, EF Morand, MF Nold
Arthritis & Rheumatology 67 (12), 3219-3225, 2015
1272015
Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
KS Yap, M Northcott, ABY Hoi, EF Morand, M Nikpour
Lupus science & medicine 2 (1), e000064, 2015
1112015
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
V Golder, R Kandane-Rathnayake, M Huq, HT Nim, W Louthrenoo, ...
The Lancet Rheumatology 1 (2), e95-e102, 2019
1102019
Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus
R Mende, FB Vincent, R Kandane-Rathnayake, R Koelmeyer, E Lin, ...
Frontiers in immunology 9, 1250, 2018
1082018
Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus
J Godsell, I Rudloff, R Kandane-Rathnayake, A Hoi, MF Nold, EF Morand, ...
Scientific reports 6 (1), 34604, 2016
1032016
Independent association of glucocorticoids with damage accrual in SLE
D Apostolopoulos, R Kandane-Rathnayake, S Raghunath, A Hoi, ...
Lupus science & medicine 3 (1), e000157, 2016
942016
Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal …
FB Vincent, M Northcott, A Hoi, F Mackay, EF Morand
Lupus 22 (9), 873-884, 2013
922013
Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic
V Golder, K Connelly, M Staples, E Morand, A Hoi
Lupus 22 (13), 1425-1430, 2013
782013
Discordance of patient and physician health status concerns in systemic lupus erythematosus
V Golder, JJY Ooi, AS Antony, T Ko, S Morton, R Kandane-Rathnayake, ...
Lupus 27 (3), 501-506, 2018
772018
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study
D Apostolopoulos, R Kandane-Rathnayake, W Louthrenoo, SF Luo, ...
The Lancet Rheumatology 2 (1), e24-e30, 2020
592020
Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort
V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ...
Arthritis research & therapy 18, 1-9, 2016
582016
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study
V Golder, R Kandane-Rathnayake, M Huq, W Louthrenoo, SF Luo, ...
The Lancet Rheumatology 1 (2), e103-e110, 2019
532019
The need to define treatment goals for systemic lupus erythematosus
K Franklyn, A Hoi, M Nikpour, EF Morand
Nature Reviews Rheumatology 10 (9), 567-571, 2014
502014
系统目前无法执行此操作,请稍后再试。
文章 1–20